Navigation Links
Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
Date:8/3/2011

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer.  Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610.  The initial agreement, signed in February 2011, for Proacta's hypoxia-activated pro-drug, PR509, granted Yakult research, development and commercialization rights to PR509 in Japan.

(Logo:  http://photos.prnewswire.com/prnh/20110803/LA45514LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b)

"Based on recent pre-clinical study results, we believe that PR610 could perform very well in the clinic," said John C. Gutheil, MD, Proacta's CEO. "We have developed a strong relationship with Yakult in the short time that we have been working together. We are delighted that Yakult is interested in PR610 and that they share our optimism regarding the potential of this molecule."

Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division/ Managing Executive Officer, Member of the Board of Yakult, said, "We are pleased to have the opportunity to expand our collaborative research, development, and commercialization agreement with Proacta to include PR610. This molecule has shown unique promise and provides Yakult with an option on two promising molecules within Proacta's hypoxia-activated irreversible multi-kinase inhibitors portfolio for the treatment of cancer. We look forward to the continued progress and advancement of the program so that we can more quickly bring promising new treatments to patients suffering from cancer."

About PR509 and PR610

PR509 and PR610 are Proacta's proprietary hypoxia-activated irreversible multi-kinase inhibitors discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand.  Reversible multi-kinase inhibitors (MKI) are currently in use for the treatment of several types of cancer.  However, resistance often develops to reversible MKI's.  In addition, reversible MKI's have side effects that limit their use at higher doses.  Both PR509 and PR610 utilize an irreversible MKI that is activated only in areas of severe hypoxia, a characteristic of most solid tumors.  Localized release of the irreversible MKI leads to higher concentrations in the tumor relative to normal tissues, which should result in improved efficacy and fewer side effects.  In addition, irreversible MKI inhibitors are not effected by some of the resistance mechanisms that limit use of reversible MKI inhibitors.

Clinical Development Status

PR509 and PR610 are currently targeted for development in non-small cell lung cancer resistant to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib, where an effective treatment has yet to be established.  In addition to NSCLC, Proacta expects to evaluate the molecules in other cancers such as gastric, breast, and pancreatic that are currently treated with first-generation reversible tyrosine kinase inhibitors.

About Proacta Incorporated

Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta is currently conducting a phase II study of PR104, a hypoxia activated alkylator, in patients with relapsed or refractory leukemia.  In addition, Proacta has a pipeline of hypoxia-activated prodrugs for the treatment of cancer that are licensed from the University of Auckland in New Zealand.  For more information on Proacta, visit the Proacta web site at www.proacta.com.

About Yakult

Yakult is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. With respect to its pharmaceutical business, Yakult has an emerging presence in oncology. For more information on Yakult, visit: http://www.yakult.co.jp/english/index.html or view the following company profile:

http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf


'/>"/>
SOURCE Proacta Incorporated; Yakult Honsha Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proactas PR509 Compound
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Genta Incorporated Announces Third Quarter 2007 Financial Results
4. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
5. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
7. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
8. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
9. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
10. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
11. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):